title: Clinical outcome of HER2-positive breast cancer patients after failure on adjuvant trastuzumab: the potential of the time to relapse.
authors.affiliation: Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Di Cosimo
authors.affiliation: Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Serpico
authors.affiliation: Department of Oncology, Istituto di Ricerche Farmacologiche "Mario Negri" - IRCCS, Milan, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Porcu
authors.affiliation: Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Molino
authors.affiliation: Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Fanetti
authors.affiliation: Department of Oncology, Istituto di Ricerche Farmacologiche "Mario Negri" - IRCCS, Milan, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Torri
authors.affiliation: Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
authors.forename: F
authors.initials: F
authors.lastname: de Braud
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D005260:Female; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018719:Erb-b2 Receptor Tyrosine Kinases